Medifast Clinical Studies
Medifast Meal Replacements and Supplements have been clinically proven in studies conducted by the Johns Hopkins University School of Medicine and The National Institutes of Health.
In the study conducted by Dr. Cheskin and Dr. Crowell at the Johns Hopkins University School of Medicine, males lost an average of 67.41 pounds and females lost an average of 47.5 pounds over a sixteen-week period.
To read more about these studies, please click on the links below
NUTRITIONAL FACTS (download guides and charts here)
John Hopkins Weight Management Center
John Hopkins Bloomberg School of Public Health
The University of Vermont at Burlington
Johns Hopkins Univ. Bloomberg Sch. of Public Health’s Nutrition & Health Research Clinic
NUTRITIONAL FACTS(download guides and charts here)
All the following informational documents are available to view.
Click on the links to download:
Medifast Product Claims Chart: (PDF)
-categorically identifies each Medifast product according to the following: diabetic, vegetarian, kosher dairy, kosher parve, contains whey, low lactose, lactose free, caffeine content, gluten, contains milk, contains egg, contains fish, contains shellfish, contains tree nuts, contains wheat, contains peanuts, contains soy.
Medifast Product Nutrition Guide: (PDF)
-
complete listing of ingredients and nutritional information for all Medifast products.
Medifast Product Allergen Claims: (PDF)
-
complete listing of allergen claims for all Medifast meals.
Physician Information Sheet: (PDF) If you are interested in discussing Medifast with your physician, please print this file and take it to your next appointment
John Hopkins Weight Management Center
In clinical studies conducted by Johns Hopkins, researchers found that the vast majority of patients (91% of males and 72% of females) lost more than 40 lbs. on the Medifast program in 16 weeks. Researchers concluded that weight loss programs by Medifast provide a safe, effective means of weight reduction and are accompanied by significant improvements in coexisting health problems.
John Hopkins Bloomberg School of Public Health
Currently studying the efficacy of Medifast Plus for Diabetics. The objective is to compare Medifast Plus for Diabetics to basic nutrition recommendations provided by the ADA.
After the first year, preliminary results of the study show that volunteers using Medifast Plus for Diabetics lost twice as much weight with an average weight loss of 16 pounds. They were also twice as likely to stay with the diet.
To learn more about this study please download the Type II Diabetes Study (PDF format).
The University of Vermont at Burlington
The University of Vermont at Burlington selected Medifast Products for its NIH-commissioned Obesity Study entitled "Energy Metabolism in the Post-Obese State" underway at The University of Vermont. This 4-year study will help define the metabolic consequences of the mutation in the B3AR gene in the regulation of daily energy expenditure and fat metabolism in older women. Researchers at the University of Vermont chose to use Medifast and Take Shape products in the study based on the recommendation of Dr. Lawrence Cheskin, Director of the Weight Management Center at Johns Hopkins University. "Medifast has been clinically tested and proven to be a safe and effective means of weight loss"
Johns Hopkins Univ. Bloomberg Sch. of Public Health’s Nutrition & Health Research Clinic
Multicenter Evaluation of Health Benefits and Weight Loss on the Medifast Weight Management Program:
The purpose of the investigation was to evaluate the efficacy of a medically supervised, protein-supplemented, modified fasting program for weight reduction and to evaluate the impact of weight reduction on coexisting health problems. The center selected Medifast products (Medifast 55 and Medifast 70) to provide the protein and calorie requirements necessary for the study. Researchers conducted an investigation of randomly selected patient charts from Medifast clinics across the nation. The results of the study concluded that medically supervised, protein-sparing, modified fasts offer a safe and effective means of weight reduction and are accompanied by significant improvements in coexisting health problems. Of the samples taken, males lost an average of 67 pounds and females lost an average of 47 pounds during fasting. The study found significant reductions in systolic and diastolic blood pressure, total cholesterol and triglycerides, as well as the normalizing of blood pressure in hypertensive patients. Efficacy of Two Diet Plans Designed for People with Type 2 Diabetes on Weight and Health Measures
The Johns Hopkins University Bloomberg School of Public Health studied the efficacy of the Medifast Plus for Diabetics program, developed to help control the weight of Type II diabetes. The researchers randomized two groups of Type II diabetic volunteers: one group participated in the Medifast Plus for Diabetics modified meal replacement diet and the other group participated in a diet based on ADA nutrition guidelines. Both groups in the study shared the same guidance from the doctors, counselors and dietitians. According to the results, dieters on Medifast lost twice as much weight after 34 weeks: an average of 16 pounds, compared to only 8 pounds on the ADA diet. The weight loss on Medifast resulted in significant reductions in blood glucose and insulin levels compared to pre-treatment values. Perhaps more importantly, significantly more individuals in the Medifast group were able to reduce their use of diabetes medications compared to those in the ADA diet group, and after 86-weeks, 36% of subjects on Medifast were off of their blood sugar medications, entirely.
National Institutes of Health
Impaired Capacity to Lose Visceral Adipose Tissue During Weight Reduction in Obese Postmenopausal Women with the Trp64Arg ß3-Adrenoceptor Gene Variant
The study examined whether women on a weight-loss program who are carriers of a genetic variant (Trp64Arg) lose less visceral fat than women who do not have this gene. Participants entered a medically supervised weight-loss program aimed at reducing body weight to less than 120 percent of ideal value.
Food was selected with dietitian supervision, with or without the inclusion of Medifast Meals. Results from the study showed that reductions in body weight, BMI, total fat mass and fat-free mass were not significantly different between carriers and non-carriers of the variant. Both groups experienced significant reductions in body weight (31.0 – 36.1 lbs.).